This is in agreement with a previous study on acute myeloid leukemia on the interplay between G6PD inhibition and mTORC1 activity [43], since mTOR is a conserved serine/threonine kinase controlling cell growth and metabolism in response to nutrients, growth factors, cellular energy, and stress [44]. The gene discussed is MARK2; the disease is acute myeloid leukemia.